Dr Agarwals Health Care Ltd
Incorporated in 2010,[1]Dr. Agarwal’s Health Care offers a wide array of eye care services, which include cataract and refractive surgeries, consultations, diagnoses, and non-surgical treatments. Additionally, they provide optical products, contact lenses, accessories, and pharmaceutical items related to eye care. [2]
- Market Cap ₹ 13,710 Cr.
- Current Price ₹ 433
- High / Low ₹ 568 / 327
- Stock P/E 118
- Book Value ₹ 61.1
- Dividend Yield 0.00 %
- ROCE 9.99 %
- ROE 4.76 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 41.7% CAGR over last 5 years
Cons
- Stock is trading at 7.09 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 7.83% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE 500 BSE Healthcare Nifty 500 BSE IPO BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 531 | 471 | 696 | 1,018 | 1,332 | 1,711 | 1,877 | |
| 407 | 387 | 510 | 743 | 965 | 1,248 | 1,367 | |
| Operating Profit | 124 | 85 | 186 | 275 | 367 | 463 | 510 |
| OPM % | 23% | 18% | 27% | 27% | 28% | 27% | 27% |
| 13 | 6 | 17 | 14 | 44 | 43 | 47 | |
| Interest | 54 | 44 | 49 | 76 | 101 | 115 | 101 |
| Depreciation | 93 | 95 | 98 | 128 | 170 | 231 | 249 |
| Profit before tax | -11 | -48 | 57 | 84 | 141 | 160 | 207 |
| Tax % | 82% | 21% | 24% | -24% | 32% | 31% | |
| -21 | -59 | 43 | 103 | 95 | 110 | 145 | |
| EPS in Rs | 2.64 | 3.64 | |||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 35% |
| TTM: | 25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 42% |
| 3 Years: | 26% |
| TTM: | 33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 8% |
| Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 8 | 9 | 32 | 32 |
| Reserves | 242 | 177 | 206 | 622 | 1,330 | 1,835 | 1,899 |
| 162 | 185 | 633 | 857 | 966 | 961 | 983 | |
| 339 | 417 | 179 | 336 | 445 | 837 | 873 | |
| Total Liabilities | 751 | 787 | 1,025 | 1,823 | 2,751 | 3,665 | 3,786 |
| 551 | 575 | 701 | 1,293 | 1,746 | 2,523 | 2,722 | |
| CWIP | 8 | 11 | 28 | 99 | 118 | 153 | 163 |
| Investments | 1 | 0 | 0 | 34 | 471 | 264 | 208 |
| 192 | 201 | 295 | 397 | 416 | 724 | 693 | |
| Total Assets | 751 | 787 | 1,025 | 1,823 | 2,751 | 3,665 | 3,786 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 103 | 99 | 164 | 233 | 346 | 360 | |
| -85 | -46 | -155 | -509 | -914 | -750 | |
| -73 | -37 | 35 | 303 | 553 | 382 | |
| Net Cash Flow | -56 | 17 | 44 | 27 | -15 | -8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 36 | 36 | 30 | 27 | 27 | 26 |
| Inventory Days | 178 | 169 | 144 | 116 | 138 | 181 |
| Days Payable | 340 | 452 | 389 | 326 | 355 | 345 |
| Cash Conversion Cycle | -126 | -247 | -215 | -183 | -190 | -138 |
| Working Capital Days | -31 | -47 | -50 | -62 | -65 | -44 |
| ROCE % | -1% | 17% | 13% | 11% | 10% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
23h - Of Schedule of Analyst / Investors Meet, is attached.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
28 Jan - Board to approve Q3/9M Dec 31, 2025 results on Feb 3; analyst call Feb 4, 11:30 IST.
-
Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2025
28 Jan - Board meeting Feb 03, 2026 to approve Q3/9M Dec 31, 2025 results; analyst call Feb 04, 2026.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 12 Jan
- Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 6 Jan
Concalls
-
Nov 2025Transcript PPT
-
Sep 2025Transcript PPT
-
Aug 2025Transcript PPT REC
-
Jun 2025Transcript PPT
-
Feb 2025Transcript PPT REC
Largest Eyecare Service Provider[1]
Dr. Agarwal is India's largest eye care service chain with a 25% market share. It is the largest company by revenue in FY23, with more than two times the revenue from operations of the second-largest eye care service chain in the country.